Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
Acta Neuropathol
    May 2026
  1. GOVAERTS CW, van Dijk JMC, van der Hoorn A, Kruyt FAE, et al
    Future directions in the treatment of brain metastases: evaluating the role of cellular players in the tumour microenvironment.
    Acta Neuropathol. 2026;151:58.
    >> Share

    April 2026
  2. RAHMANZADE R, Schweizer L, Schmid S, Lausova T, et al
    Loss of meningothelial identity and mesenchymal fate switching in NF2-mutant meningiomas.
    Acta Neuropathol. 2026;151:46.
    >> Share

  3. ZHENG Y, Alzoubi I, Graeber MB, Anand A, et al
    Consensus statement on microglial and macrophage functions in gliomas.
    Acta Neuropathol. 2026;151:39.
    >> Share

    March 2026
  4. TAUZIEDE-ESPARIAT A, Castel D, Ajlil Y, Metais A, et al
    H3K27ME3 loss in diffuse midline gliomas lacking H3K27M or EZHIP expressions, a potential diagnostic pitfall!
    Acta Neuropathol. 2026;151:24.
    >> Share

  5. TLAIS D, Zhang Q, Roach JT, Tinkle CL, et al
    Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
    Acta Neuropathol. 2026;151:22.
    >> Share

    February 2026
  6. FUJIMOTO K, Honda-Kitahara M, Hattori N, Matsushita Y, et al
    Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
    Acta Neuropathol. 2026;151:15.
    >> Share

    January 2026
  7. BRAND F, Rose LS, Akbarzadeh AH, Weber CAM, et al
    Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.
    Acta Neuropathol. 2026;151:6.
    >> Share

    November 2025
  8. FURST A, Ruf V, Fiedler C, Rutkowski S, et al
    IDH mutations are rare events in SHH medulloblastoma.
    Acta Neuropathol. 2025;150:55.
    >> Share

    October 2025
  9. PFAFF E, Schramm K, Blattner-Johnson M, Jones BC, et al
    Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM.
    Acta Neuropathol. 2025;150:42.
    >> Share

  10. LOTSCH C, Warta R, Liu F, Jungwirth G, et al
    Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells.
    Acta Neuropathol. 2025;150:41.
    >> Share

    September 2025
  11. JURGENSEN L, Benfatto S, Schmid S, Daenekas B, et al
    In silico purification improves DNA methylation-based classification rates of pediatric low-grade gliomas.
    Acta Neuropathol. 2025;150:34.
    >> Share

  12. ARTZI SB, Klausen MN, Harwood DSL, Michaelsen SR, et al
    Spatial transcriptomic analysis reveals lack of response to PD-1 blockade in recurrent glioblastoma.
    Acta Neuropathol. 2025;150:29.
    >> Share

  13. NANDAKUMAR S, Mehine M, Kemel Y, Bandlamudi C, et al
    Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors.
    Acta Neuropathol. 2025;150:27.
    >> Share

  14. COSTA FD, Alves de Castro JV, Gomes YM, Kulikowski LD, et al
    Pineal region high-grade neuroepithelial tumors with NTRK fusions map to the novel methylation class "diffuse high-grade glioma, IDH-wild type, subtype E".
    Acta Neuropathol. 2025;150:26.
    >> Share

    August 2025
  15. WEBER KJ, Dettki M, Munzberg M, Zeiner PS, et al
    DNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma.
    Acta Neuropathol. 2025;150:21.
    >> Share

  16. MIKKELSEN MK, Li X, Yu K, High AA, et al
    Diffuse leptomeningeal glioneuronal tumor (DLGNT): a comprehensive clinical and molecular analysis.
    Acta Neuropathol. 2025;150:18.
    >> Share

  17. KECK MK, Al-Hussaini M, Amayiri N, Yiadom AAB, et al
    PLAG1 fusions define a third subtype of CNS embryonal tumor with PLAG family gene alteration.
    Acta Neuropathol. 2025;150:12.
    >> Share

    June 2025
  18. COTTER JA, Markowitz AL, Castaneda E, Yen CY, et al
    CNS methylation classifiers may misclassify normal developing cerebellar cortex as medulloblastoma.
    Acta Neuropathol. 2025;149:66.
    >> Share

  19. KRECH M, Muench A, Teichmann D, Kuzman P, et al
    Outcome-associated factors in a molecularly defined cohort of central neurocytoma.
    Acta Neuropathol. 2025;149:61.
    >> Share

    April 2025
  20. DWARSHUIS G, Kroon LL, Brandsma D, Noske DP, et al
    Liquid biopsies for the monitoring of gliomas and brain metastases in adults.
    Acta Neuropathol. 2025;149:37.
    >> Share

  21. SINGH O, Dampier C, Abdullaev Z, Dazelle K, et al
    Diffuse astrocytoma, AYA-type, frequently MAPK-altered: report of 45 patients.
    Acta Neuropathol. 2025;149:32.
    >> Share

    March 2025
  22. PURKAIT S, Praeger S, Felsberg J, Pauck D, et al
    Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymoma.
    Acta Neuropathol. 2025;149:29.
    >> Share

    February 2025
  23. HINZ F, Friedel D, Korshunov A, Ippen FM, et al
    IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spread.
    Acta Neuropathol. 2025;149:12.
    >> Share

  24. FRIKER LL, Perwein T, Waha A, Dorner E, et al
    MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.
    Acta Neuropathol. 2025;149:11.
    >> Share

    January 2025
  25. PAGANI F, Orzan F, Lago S, De Bacco F, et al
    Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.
    Acta Neuropathol. 2025;149:8.
    >> Share

  26. MADLENER S, Stepien N, Senfter D, Mayr L, et al
    Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method.
    Acta Neuropathol. 2025;149:5.
    >> Share

    November 2024
  27. MIKOLAJEWICZ N, Tatari N, Wei J, Savage N, et al
    Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.
    Acta Neuropathol. 2024;148:74.
    >> Share

  28. JOTANOVIC J, Boldt HB, Burton M, Andersen MS, et al
    Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.
    Acta Neuropathol. 2024;148:68.
    >> Share

    October 2024
  29. CHUNG HJ, Rajan S, Wu Z, Ferrone CK, et al
    MYB/MYBL1-altered gliomas frequently harbor truncations and non-productive fusions in the MYB and MYBL1 genes.
    Acta Neuropathol. 2024;148:54.
    >> Share

  30. GHISAI SA, van Hijfte L, Vallentgoed WR, Tesileanu CMS, et al
    Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
    Acta Neuropathol. 2024;148:50.
    >> Share

    September 2024
  31. NUECHTERLEIN N, Cimino S, Shelbourn A, Ha V, et al
    HOXD12 defines an age-related aggressive subtype of oligodendroglioma.
    Acta Neuropathol. 2024;148:41.
    >> Share

  32. STEGAT L, Eckhardt A, Gocke A, Neyazi S, et al
    Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance.
    Acta Neuropathol. 2024;148:40.
    >> Share

  33. SOL N, Kooi EJ, Pages-Gallego M, Brandsma D, et al
    Glioblastoma, IDH-wildtype with primarily leptomeningeal localization diagnosed by nanopore sequencing of cell-free DNA from cerebrospinal fluid.
    Acta Neuropathol. 2024;148:35.
    >> Share

  34. HENCH J, Hultschig C, Bratic Hench I, Sadasivan H, et al
    Rapid brain lymphoma diagnostics through nanopore sequencing of cytology-negative cerebrospinal fluid.
    Acta Neuropathol. 2024;148:36.
    >> Share

    August 2024
  35. TERANISHI Y, Yurchenko A, Tran S, Sievers P, et al
    Correlation between natural history and multi-omics profiling of meningiomas in NF2-related schwannomatosis suggests role of methylation group and immune microenvironment in tumor growth rate.
    Acta Neuropathol. 2024;148:30.
    >> Share

  36. AN S, McCortney K, Walshon J, Leonard K, et al
    Methylation profiling of plasma cell-free DNA in pediatric brain tumor patients.
    Acta Neuropathol. 2024;148:29.
    >> Share

  37. LECLAIR NK, Lucas CG, Mirchia K, McCortney K, et al
    The RNA-binding protein IGF2BP1 regulates stability of mRNA transcribed from FOXM1 target genes in hypermitotic meningiomas.
    Acta Neuropathol. 2024;148:28.
    >> Share

  38. LE QUANG M, Trinquet A, Siegfried A, de Barros A, et al
    FGFR1 wild-type rosette-forming glioneuronal tumours.
    Acta Neuropathol. 2024;148:26.
    >> Share

  39. ZHANG KY, Parker M, Weber-Levine C, Kalluri A, et al
    ASXL1 inactivation and reduced H3K27me3 across central nervous system tumors.
    Acta Neuropathol. 2024;148:19.
    >> Share

  40. MAAS SLN, Hielscher T, Sievers P, Hovestadt V, et al
    Loss over 5% of chromosome 1p is a clinically relevant and applicable cut-off for increased risk of recurrence in meningioma.
    Acta Neuropathol. 2024;148:17.
    >> Share

    July 2024
  41. PRIESTERBACH-ACKLEY LP, Cordier F, de Witt Hamer P, Snijders TJ, et al
    Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4.
    Acta Neuropathol. 2024;148:12.
    >> Share

  42. SIEVERS P, Bielle F, Gobel K, Schrimpf D, et al
    Identification of a putative molecular subtype of adult-type diffuse astrocytoma with recurrent MAPK pathway alterations.
    Acta Neuropathol. 2024;148:7.
    >> Share

  43. RICHARDSON TE, Walker JM, Hambardzumyan D, Brem S, et al
    Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.
    Acta Neuropathol. 2024;148:5.
    >> Share

    June 2024
  44. OKONECHNIKOV K, Schrimpf D, Koster J, Sievers P, et al
    Clinically unfavorable transcriptome subtypes of non-WNT/non-SHH medulloblastomas are associated with a predominance in proliferating and progenitor-like cell subpopulations.
    Acta Neuropathol. 2024;147:95.
    >> Share

    May 2024
  45. LIN AL, Rudneva VA, Richards AL, Zhang Y, et al
    Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
    Acta Neuropathol. 2024;147:85.
    >> Share

  46. SCHULLER U, Gocke A, Godbole S, Delbridge C, et al
    Anaplastic histology and distinct molecular features in a small series of spinal cord ependymomas.
    Acta Neuropathol. 2024;147:83.
    >> Share

    April 2024
  47. NASSIRI F, Ajisebutu A, Patil V, Mamatjan Y, et al
    Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.
    Acta Neuropathol. 2024;147:68.
    >> Share

    March 2024
  48. REDMER T, Schumann E, Peters K, Weidemeier ME, et al
    Correction to: MET receptor serves as a promising target in melanoma brain metastases.
    Acta Neuropathol. 2024;147:63.
    >> Share

  49. ZAKIMI N, Nguyen MP, Raleigh DR
    Gene transcript fusions are associated with clinical outcomes and molecular groups of meningiomas.
    Acta Neuropathol. 2024;147:57.
    >> Share

    February 2024
  50. REDMER T, Schumann E, Peters K, Weidemeier ME, et al
    MET receptor serves as a promising target in melanoma brain metastases.
    Acta Neuropathol. 2024;147:44.
    >> Share

  51. HARMANCI AS, Boudreau B, Lau S, Hosseingholi Nouri S, et al
    Aggressive human MenG C meningiomas have a molecular counterpart in canines.
    Acta Neuropathol. 2024;147:42.
    >> Share

  52. ZAKIMI N, Mazcko CN, Toedebusch C, Tawa G, et al
    Canine meningiomas are comprised of 3 DNA methylation groups that resemble the molecular characteristics of human meningiomas.
    Acta Neuropathol. 2024;147:43.
    >> Share

  53. RAHMANZADE R, Sahm F
    Reply: pineal parenchymal tumors of intermediate differentiation: in need of a stringent definition to avoid confusion.
    Acta Neuropathol. 2024;147:35.
    >> Share

  54. VASILJEVIC A
    Pineal parenchymal tumors of intermediate differentiation: in need of a stringent definition to avoid confusion. Scientific commentary on 'Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate diffe
    Acta Neuropathol. 2024;147:34.
    >> Share

    January 2024
  55. NEYAZI S, Yamazawa E, Hack K, Tanaka S, et al
    Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.
    Acta Neuropathol. 2024;147:22.
    >> Share

  56. DREXLER R, Khatri R, Schuller U, Eckhardt A, et al
    Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma.
    Acta Neuropathol. 2024;147:21.
    >> Share

  57. DOTTERMUSCH M, Ryba A, Ricklefs FL, Flitsch J, et al
    Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
    Acta Neuropathol. 2024;147:16.
    >> Share

    December 2023
  58. HADAD S, Gupta R, Oberheim Bush NA, Taylor JW, et al
    "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Acta Neuropathol. 2023;147:3.
    >> Share

  59. AUFFRET L, Ajlil Y, Tauziede-Espariat A, Kergrohen T, et al
    A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Acta Neuropathol. 2023;147:2.
    >> Share

  60. HICKMAN RA, Gedvilaite E, Ptashkin R, Reiner AS, et al
    CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas.
    Acta Neuropathol. 2023;146:845-847.
    >> Share

  61. RAHMANZADE R, Pfaff E, Banan R, Sievers P, et al
    Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics.
    Acta Neuropathol. 2023;146:853-856.
    >> Share

    October 2023
  62. MAAS SLN, Sievers P, Weber DC, Weller M, et al
    Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042.
    Acta Neuropathol. 2023 Oct 19. doi: 10.1007/s00401-023-02642.
    >> Share

  63. ROBERTS HJ, Ji S, Picca A, Sanson M, et al
    Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.
    Acta Neuropathol. 2023 Oct 18. doi: 10.1007/s00401-023-02640.
    >> Share

  64. PICARD D, Felsberg J, Langini M, Stachura P, et al
    Integrative multi-omics reveals two biologically distinct groups of pilocytic astrocytoma.
    Acta Neuropathol. 2023;146:551-564.
    >> Share

    September 2023
  65. BOETTO J, Plu I, Ducos Y, Blouin A, et al
    Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes.
    Acta Neuropathol. 2023 Sep 26. doi: 10.1007/s00401-023-02635.
    >> Share

  66. TRAN QT, Upadhyaya SA, Billups CA, Onar-Thomas A, et al
    DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts.
    Acta Neuropathol. 2023;146:543-545.
    >> Share

  67. JOHANN PD, Altendorf L, Efremova EM, Holsten T, et al
    Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics.
    Acta Neuropathol. 2023;146:527-541.
    >> Share

    August 2023
  68. WIRSCHING HG, Felsberg J, Prummer M, Moisoiu V, et al
    Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival.
    Acta Neuropathol. 2023 Aug 13. doi: 10.1007/s00401-023-02617.
    >> Share

    July 2023
  69. WILLIAMS EA, Brastianos PK, Wakimoto H, Zolal A, et al
    A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Acta Neuropathol. 2023 Jul 31. doi: 10.1007/s00401-023-02609.
    >> Share

    June 2023
  70. MEDICI G, Freudenmann LK, Velz J, Wang SS, et al
    A T-cell antigen atlas for meningioma: novel options for immunotherapy.
    Acta Neuropathol. 2023 Jun 27. doi: 10.1007/s00401-023-02605.
    >> Share

  71. MADLENER S, Furtner J, Stepien N, Senfter D, et al
    Clinical applicability of miR517a detection in liquid biopsies of ETMR patients.
    Acta Neuropathol. 2023;145:843-846.
    >> Share

    May 2023
  72. WANG JZ, Patil V, Liu J, Dogan H, et al
    Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Acta Neuropathol. 2023 May 12. doi: 10.1007/s00401-023-02584.
    >> Share

    April 2023
  73. KORSHUNOV A, Okonechnikov K, Schrimpf D, Tonn S, et al
    Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Acta Neuropathol. 2023 Apr 24. doi: 10.1007/s00401-023-02575.
    >> Share

  74. WANG JZ, Patil V, Liu J, Dogan H, et al
    Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Acta Neuropathol. 2023 Apr 24. doi: 10.1007/s00401-023-02571.
    >> Share

  75. GODDARD J, Castle J, Southworth E, Fletcher A, et al
    Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
    Acta Neuropathol. 2023 Apr 4. doi: 10.1007/s00401-023-02566.
    >> Share

    March 2023
  76. BOGUMIL H, Sill M, Schrimpf D, Ismer B, et al
    Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
    Acta Neuropathol. 2023 Mar 18. doi: 10.1007/s00401-023-02558.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016